Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:38:34 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



News for U:TGTX from 2025-02-07 to 2026-02-06 - 32 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-02-06 07:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2026-01-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2026-01-13 16:25U:TGTXNews ReleaseTG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
2026-01-07 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-11-28 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-19 08:30U:TGTXNews ReleaseTG Therapeutics Makes 2025 Deloitte Technology Fast 500(TM) List of America's Fastest-Growing Companies
2025-11-10 16:00U:TGTXNews ReleaseTG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
2025-11-03 07:00U:TGTXNews ReleaseTG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
2025-10-31 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
2025-10-28 07:30U:TGTXNews ReleaseTG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
2025-09-24 09:10U:TGTXNews ReleaseNew Data for BRIUMVI(TM) Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
2025-09-10 07:31U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2025-09-08 07:30U:TGTXNews ReleaseTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
2025-09-04 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2025-09-03 07:30U:TGTXNews ReleaseTG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
2025-08-28 08:00U:TGTXNews ReleaseTG Therapeutics to Participate in the Cantor Global Healthcare Conference
2025-08-04 07:00U:TGTXNews ReleaseTG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
2025-07-30 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
2025-06-06 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-06-02 08:00U:TGTXNews ReleaseTG Therapeutics to Participate in the Jefferies Global Healthcare Conference
2025-05-30 07:30U:TGTXNews ReleaseTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
2025-05-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
2025-05-05 07:00U:TGTXNews ReleaseTG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
2025-04-30 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
2025-04-10 07:30U:TGTXNews ReleaseTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
2025-04-08 07:30U:TGTXNews ReleaseTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
2025-04-07 07:30U:TGTXNews ReleaseTG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
2025-03-07 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
2025-03-03 07:00U:TGTXNews ReleaseTG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI(TM) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2025-02-26 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
2025-02-18 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum